The VITROS Immunodiagnostics Products Anti-HIV 1+2 Assay: A Rapid and Reliable Method for HIV Screening.
Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnar...
| Publicado en: | Laboratory Medicine Vol. 42; no. 4; pp. 209 - 213 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
Apr2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104626509&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104626509 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00075027 4CY jtl: Laboratory Medicine issn: 00075027 maglogo: N pubinfo: dt: Apr2011 vid: 42 iid: 4 pid: 10398 pub: Oxford University Press / USA artinfo: ui: 104626509 70268019 10.1309/LMVS6PFQP97HIUYV 104626509 ppf: 209 ppct: 4 formats: fmt: @attributes: type: P tig: atl: The VITROS Immunodiagnostics Products Anti-HIV 1+2 Assay: A Rapid and Reliable Method for HIV Screening. aug: au: Thompson, Matthew P. Hidalgo, Darnely Kim, Anne Ansari, M. Qasim affil: Department of Pathology, University of Texas Southwestern Medical Center, Parkland Memorial Hospital, Dallas, TX sug: subj: AIDS Serodiagnosis Methods Health Screening Reagent Kits, Diagnostic Evaluation Human Comparative Studies Turnaround Time Chemiluminescent Measurements Sensitivity and Specificity False Negative Results False Positive Results Evaluation Research Hospitals, Community Autoanalyzers ab: Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnaround time (TAT) of the VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics, Rochester, NY) in a large community hospital setting. The assay was recently approved by the Food and Drug Administration (FDA). Methods: We compared our current Abbott HIVAB assay (Abbott Laboratories, Abbott Park, IL) with how the VITROS performed on the random access VITROS ECi/ECiQ System in a head-to-head comparison of 298 patient samples and a retrospective comparison of TAT over an 8-month period of utilization.Results: Our data indicate that the VITROS is as sensitive (100%, n=298) and more specific (98% vs 83%) than the Abbott HIVAB and has a faster average TAT (156 minutes vs 1266 minutes). Conclusions: Use of this rapid and reliable assay will lead to greater awareness of HIV status and, hopefully, a decrease in incidence of HIV disease. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|